Dialysis

Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Technology, Medical Devices, FDA, Health Technology, Professional Services, Software, Health, Data Analytics, General Health, Growth, Medicine, Mental, Business, Patient, Stryker Corporation, Gold, Business development, Acquisition, University, Marketing, 3Com, Fortune 500, Dialysis, Movement, Audit committee, Management

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors.
  • “Brent brings a wealth of healthcare expertise to the Outset board, including in growing and scaling software-enabled business models, which is well-aligned with our recurring revenue model,” said Leslie Trigg, Chair and Chief Executive Officer.
  • “As we welcome Brent, we want to also thank Katie for her service to the Outset board during a period of growth and change following our public offering,” added Ms. Trigg.
  • “We wish her well as she begins an exciting new phase of her career journey.”
    Mr. Lang will serve on the Audit Committee of the Outset board.

Kidney Patients Raise National Health Alert on Phosphorus

Retrieved on: 
Thursday, April 4, 2024
Hyperphosphatemia, Transplant, Nutrient, Hyperkalemia, Congress, Patient, Stroke, Social media, Investment, United States Senate, Phosphorus, Representative, Ways and means committee, Research, Education, Itch, Risk, ESRD, Policy, FMLA, CMS, Senate, Food, Federation, Kidney failure, Prospective payment system, Death, House, Executive (government), Louisiana House of Representatives, Graduate diploma, Dialysis, FDA, Government, Seizure, CKD, Mortality, Kidney disease, Medicare, Physician, Pharmaceutical industry

WASHINGTON, April 4, 2024 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the U.S., is raising public awareness on April 5, National Phosphorus Awareness Day, about the devastating impacts of unmanaged phosphorus levels in individuals with advanced chronic kidney disease (CKD).

Key Points: 
  • Kidney patients are at an increased risk for high phosphorus (termed hyperphosphatemia) due to their decreased kidney function and an inability to excrete excess nutrients, including phosphorus.
  • Kidney patients are medically complex and typically manage multiple co-related health conditions including hyperphosphatemia , hyperkalemia , CKD associated pruritis (CKD-aP) , and more .
  • Kidney patients and all people of goodwill involved in the fight to improve kidney health are making their voices heard by contacting their U.S.
  • Since 1969, The American Association of Kidney Patients has been a patient-led organization driving policy discussions on kidney patient care choice and medical innovation.

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Akebia, CKD, Patient, Tablet, Public, Stroke, Death, Therapy, Nephrology, Safety, Chronic kidney disease, Dialysis, Anemia, Division, Stanford University, Food, FDA, Pharmaceutical industry

Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.

Key Points: 
  • Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.
  • "As we continue to deliver on our promise for patients and public health, we are eager to closely collaborate with our partners to make this new oral treatment option available to patients."
  • Results from the INNO2VATE program were published in the New England Journal of Medicine: (N Engl J Med 2021; 384:1601-1612); (N Engl J Med 2021; 384:1589-1600).
  • See the Important Safety Information section below, including BOXED WARNING regarding increased risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access.

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Conference, Organization, Tablet, Caregiver, Anemia, Physician, CKD, Webcast, Patient, Coronary thrombosis, Stroke, AKBA, Death, Renal Support Network, Kidney disease, Nephrology, Kidney, Chronic kidney disease, Dialysis, Division, Safety, Stanford University, Food, Hypoxia, FDA, Erythropoietin, Pharmaceutical industry

CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries.

Key Points: 
  • "At Akebia we are committed to kidney patients, a dedication that has driven our team to achieve this milestone.
  • We believe this commitment uniquely positions the company to execute a successful launch designed to drive toward a potential new oral standard of care for dialysis patients."
  • Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to CKD1, which may be associated with many adverse clinical outcomes.
  • Today, most CKD patients are treated for anemia with injectable erythropoiesis-stimulating agents mostly administered at dialysis centers.

Global Medical Metal Tubing Market to Reach $1,161.9 Million, by 2030 at 7.4% CAGR: Coherent Market Insights

Retrieved on: 
Tuesday, March 26, 2024
Geography, Growth, Prevalence, Application, Risk, Conditional sentence, Ametek, Stainless steel, Teleflex, Originality, OEM, Infection, Dialysis, Precision, Catheter, VPS, Administration, Medical device

The medical metal tubing market is expected to witness significant growth during the forecast period due to the growing demand for medical metal tubing in the healthcare sector.

Key Points: 
  • The medical metal tubing market is expected to witness significant growth during the forecast period due to the growing demand for medical metal tubing in the healthcare sector.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4052
    Advancements in technology, such as the development of biocompatible and antimicrobial medical metal tubing, are further propelling the growth of the medical metal tubing market.
  • Additionally, the increasing adoption of minimally invasive surgeries and the rising demand for precision medical devices are creating lucrative opportunities for the medical metal tubing market.
  • In conclusion, the medical metal tubing market is experiencing considerable growth due to the growing demand for medical metal tubing in the healthcare sector and advancements in technology driving market growth.

Global Medical Metal Tubing Market to Reach $1,161.9 Million, by 2030 at 7.4% CAGR: Coherent Market Insights

Retrieved on: 
Tuesday, March 26, 2024
Geography, Growth, Prevalence, Application, Risk, Conditional sentence, Ametek, Stainless steel, Teleflex, Originality, OEM, Infection, Dialysis, Precision, Catheter, VPS, Administration, Medical device

The medical metal tubing market is expected to witness significant growth during the forecast period due to the growing demand for medical metal tubing in the healthcare sector.

Key Points: 
  • The medical metal tubing market is expected to witness significant growth during the forecast period due to the growing demand for medical metal tubing in the healthcare sector.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4052
    Advancements in technology, such as the development of biocompatible and antimicrobial medical metal tubing, are further propelling the growth of the medical metal tubing market.
  • Additionally, the increasing adoption of minimally invasive surgeries and the rising demand for precision medical devices are creating lucrative opportunities for the medical metal tubing market.
  • In conclusion, the medical metal tubing market is experiencing considerable growth due to the growing demand for medical metal tubing in the healthcare sector and advancements in technology driving market growth.

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Retrieved on: 
Friday, March 22, 2024
Inclusion, Fresenius Medical Care, Letter, Science Based Targets initiative, Kidney, Patient, UN Women, Climate, Diversity, Science, Woman, Patient satisfaction, Annual report, The Annual Report, Dialysis, FME, BAD, German, Paris Agreement

Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

Key Points: 
  • Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
  • Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: "The year 2023 was a transformative one for Fresenius Medical Care, as we set out to achieve important structural, operational, and cultural changes.
  • The 2023 Annual Report summarizes Fresenius Medical Care's steps to successfully deliver on the transformation and contains Fresenius Medical Care's Non-financial Group Report, providing a comprehensive overview of its progress of sustainability activities and achievements in three strategic focus areas:
    Enhancing quality care and access to health care: In about 4,000 dialysis clinics in around 50 countries worldwide, Fresenius Medical Care provided care for over 332,000 patients in 2023.
  • It is available for download as pdf-file on the company's website: Annual reports | Fresenius Medical Care .

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Retrieved on: 
Tuesday, March 19, 2024
Ready4, Fresenius Medical Care, Learning, Safety, Kidney, Augmented reality, Education, Knowledge, Hospital, Emergency medicine, Augment, Intensive care medicine, Dialysis, FME, BAD, ICU, Nursing, Health, Medtech

The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.

Key Points: 
  • The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
  • Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care," says Dr. Katarzyna Mazur-Hofsäß, member of the Management Board of Fresenius Medical Care AG and responsible for Care Enablement, Fresenius Medical Care's MedTech segment.
  • The AR glasses provide access to the Augmented Reality learning program Ready4 multiFiltratePRO AR, which Fresenius Medical Care presented today at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.
  • Ready4 multiFiltratePRO AR has been specifically developed for use with the multiFiltratePRO, Fresenius Medical Care's Continuous Kidney Replacement Therapy system.

CMUH(Taiwan) Using AI to Monitor Home Hemodialysis

Retrieved on: 
Monday, March 18, 2024
Ultrafiltration, Blood pressure, Osmotic pressure, Chronic kidney disease, Renal replacement therapy, Patient, Peritoneal dialysis, Home hemodialysis, Fatigue, AI, Quality of life, Dehydration, Water, Safety, Dialysis, Patient safety, Family, HHD, Work, Medical device

TAICHUNG, March 18, 2024 /PRNewswire/ -- Chronic Kidney Disease has become a new "national disease" in Taiwan, and the number of patients requiring hemodialysis is increasing. Traditionally, hemodialysis patients and accompanies require at least an hour spent on commuting, and that maybe even more time consuming for those who live in suburbs. Moreover, patients almost feel tired or fatigue and need rest half a day following hemodialysis. Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients. The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation. Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine. Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Key Points: 
  • Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients.
  • The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation.
  • Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine.
  • Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

The University of Texas Health Science Center at San Antonio announces the passing of William L. Henrich, MD, president since 2009

Retrieved on: 
Friday, March 15, 2024
Alzheimer's disease, Barshop Institute, Biomedical Research, Health, Patient, History, Quality of life, Humour, University, MACP, Love, NIA, Pandemic, Dementia, Ageing, NCI, Obesity, Innovation, UT System, Diabetes, SAN, NIH, Workforce, Transplant, Intelligence, Public, FACP, Integration, News, Textbook, Cancer, Dialysis, Haematopoietic system, Family, Neurodegenerative disease, Dentistry, Growth, COVID-19, School, Life, University of Texas System, MARC, Nursing

SAN ANTONIO, Texas, March 14, 2024 /PRNewswire-PRWeb/ -- It is with profound sadness that The University of Texas of Health Science Center at San Antonio (UT Health San Antonio) announces that William L. Henrich, MD, MACP, president of UT Health San Antonio, passed away this morning, March 14, 2024. There will be announcements about Dr. Henrich's memorial services soon.

Key Points: 
  • SAN ANTONIO, Texas, March 14, 2024 /PRNewswire-PRWeb/ -- It is with profound sadness that The University of Texas of Health Science Center at San Antonio (UT Health San Antonio) announces that William L. Henrich, MD, MACP, president of UT Health San Antonio, passed away this morning, March 14, 2024.
  • Dr. Henrich was able to return as president in February 2013 and presided over the unprecedented growth experienced by UT Health San Antonio.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.
  • Monica Taylor, The University of Texas Health Science Center at San Antonio, 210-450-8970, [email protected] , https://news.uthscsa.edu/